NO20010539L - Behandling av avhengighet og avhengighet-relatert oppforsel - Google Patents
Behandling av avhengighet og avhengighet-relatert oppforselInfo
- Publication number
- NO20010539L NO20010539L NO20010539A NO20010539A NO20010539L NO 20010539 L NO20010539 L NO 20010539L NO 20010539 A NO20010539 A NO 20010539A NO 20010539 A NO20010539 A NO 20010539A NO 20010539 L NO20010539 L NO 20010539L
- Authority
- NO
- Norway
- Prior art keywords
- addiction
- treatment
- related behavior
- abuse
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Paper (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/129,253 US6057368A (en) | 1998-08-05 | 1998-08-05 | Treatment of addiction and addiction-related behavior |
US09/189,166 US6828349B1 (en) | 1998-08-05 | 1998-11-09 | Treatment of addiction and addiction-related behavior |
US09/209,952 US6541520B1 (en) | 1998-08-05 | 1998-12-11 | Treatment of addiction and addiction-related behavior |
PCT/US1999/017220 WO2000007583A2 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20010539D0 NO20010539D0 (no) | 2001-01-31 |
NO20010539L true NO20010539L (no) | 2001-04-02 |
Family
ID=27383860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20010539A NO20010539L (no) | 1998-08-05 | 2001-01-31 | Behandling av avhengighet og avhengighet-relatert oppforsel |
Country Status (24)
Country | Link |
---|---|
US (4) | US6541520B1 (no) |
EP (1) | EP1102583B1 (no) |
JP (1) | JP2002522383A (no) |
CN (1) | CN1172663C (no) |
AT (1) | ATE328588T1 (no) |
AU (1) | AU772715B2 (no) |
BR (1) | BR9912760A (no) |
CA (1) | CA2339192C (no) |
CY (1) | CY1105214T1 (no) |
CZ (1) | CZ2001394A3 (no) |
DE (1) | DE69931789T2 (no) |
DK (1) | DK1102583T3 (no) |
ES (1) | ES2267287T3 (no) |
HR (1) | HRP20010085A2 (no) |
HU (1) | HUP0103377A3 (no) |
ID (1) | ID28916A (no) |
IL (1) | IL141067A0 (no) |
MX (1) | MXPA01001268A (no) |
NO (1) | NO20010539L (no) |
NZ (1) | NZ509682A (no) |
PL (1) | PL198789B1 (no) |
PT (1) | PT1102583E (no) |
TW (1) | TWI243674B (no) |
WO (1) | WO2000007583A2 (no) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
WO2000010554A2 (en) * | 1998-08-25 | 2000-03-02 | Sepracor Inc. | Methods and compositions employing optically pure s(+) vigabatrin |
AU759756B2 (en) * | 1998-10-20 | 2003-05-01 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse |
PT1158973E (pt) * | 1999-02-24 | 2005-07-29 | Univ Cincinnati | Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos |
EP1175211A2 (en) * | 1999-04-30 | 2002-01-30 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
IT1313585B1 (it) * | 1999-07-30 | 2002-09-09 | Neuroscienze S C A R L | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
US6395783B1 (en) * | 2000-10-23 | 2002-05-28 | Brookhaven Science Associates, Llc | Treatment of PCP addiction and PCP addiction-related behavior |
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
US6462084B1 (en) * | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
US20020187996A1 (en) * | 2001-05-14 | 2002-12-12 | Dewey Stephen L. | Prevention of addiction in pain management |
US7041650B2 (en) | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7822470B2 (en) * | 2001-10-11 | 2010-10-26 | Osypka Medical Gmbh | Method for determining the left-ventricular ejection time TLVE of a heart of a subject |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
AU2003213719A1 (en) * | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US6797707B2 (en) * | 2002-03-29 | 2004-09-28 | University Of Florida | Antagonists of RF-amide neuropeptides |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
AU2003243699B2 (en) | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
AR055792A1 (es) * | 2005-05-17 | 2007-09-05 | Wm Internat Ltd | Aparato y metodo para la estabilizacion no quimica de bio-solidos |
AU2006249577A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
JP2009507081A (ja) * | 2005-09-07 | 2009-02-19 | ブレインセルス,インコーポレイティド | HDac阻害による神経発生の調整 |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
DE102006016990A1 (de) * | 2006-04-11 | 2007-10-18 | Hermann, Holger Lars, Dr. | Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen |
AU2007253814A1 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
US20100021570A1 (en) * | 2006-06-21 | 2010-01-28 | Harlan Clayton Bieley | Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke |
US20080103111A1 (en) * | 2006-06-21 | 2008-05-01 | Harlan Clayton Bieley | Smoking Cessation Treatment with Appetite Suppression |
EP2061458B1 (en) * | 2006-09-15 | 2014-12-10 | Regents of the University of Minnesota | Topiramate compositions and methods for their use |
US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
CN101636159A (zh) * | 2007-01-23 | 2010-01-27 | 公立大学法人名古屋市立大学 | 用于预防和治疗阿尔茨海默型痴呆症的药物 |
US20090041800A1 (en) | 2007-08-06 | 2009-02-12 | Synosia Therapeutics, Inc. | Methods for Treating Dependence |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
JP2011500686A (ja) * | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤 |
EA018567B1 (ru) | 2008-06-23 | 2013-08-30 | Янссен Фармацевтика Нв | Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
CA2776160A1 (en) * | 2009-09-30 | 2011-04-07 | Harlan Clayton Bieley | Smoking cessation with body weight maintenance and nutritional supplement |
AU2010300641B2 (en) | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011106692A2 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
US20120046232A1 (en) * | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
CN103370058A (zh) | 2010-12-22 | 2013-10-23 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
CN107412173A (zh) | 2010-12-23 | 2017-12-01 | 普渡制药公司 | 抗篡改固体口服剂型 |
US20140072935A1 (en) * | 2012-09-07 | 2014-03-13 | Tina M. Herron | Method of Regulating Caloric Intake |
RU2673818C2 (ru) | 2012-11-30 | 2018-11-30 | Экьюра Фармасьютикалз, Инк. | Саморегулируемое высвобождение фармацевтического ингредиента |
MX2015010041A (es) | 2013-02-05 | 2015-10-30 | Purdue Pharma Lp | Formulacion farmaceuticas resistentes a la alteracion. |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
EP3122337A4 (en) | 2014-03-26 | 2017-11-08 | Sun Pharma Advanced Research Company Ltd | Abuse deterrent immediate release coated reservoir solid dosage form |
US9878138B2 (en) * | 2014-06-03 | 2018-01-30 | Pop Test Abuse Deterrent Technology Llc | Drug device configured for wireless communication |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CN114903006A (zh) * | 2021-02-09 | 2022-08-16 | 中国科学院脑科学与智能技术卓越创新中心 | 一种非人灵长类动物物质成瘾模型的构建方法与应用 |
EP4334282A1 (en) * | 2021-05-05 | 2024-03-13 | Mind Medicine, Inc. | Mdma enantiomers |
CN115386421A (zh) * | 2022-06-23 | 2022-11-25 | 江苏华熙益能生物科技有限公司 | 烟叶用香精、制备方法及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639607A (en) | 1970-11-02 | 1972-02-01 | Jack E Phillips | Method for treating the tobacco smoking habit |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
GB2133002B (en) | 1982-12-30 | 1986-01-29 | Merrell Toraude & Co | Process for preparing 4-amino-5-hexenoic acid |
GB8311804D0 (en) | 1983-04-29 | 1983-06-02 | Merrell Toraude & Co | Treatment of seizure disorders and pharmaceutical compositions |
US4595697A (en) | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
JPH03500411A (ja) | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
EP0509180A1 (en) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
GB9125615D0 (en) * | 1991-12-02 | 1992-01-29 | Wyeth John & Brother Ltd | Amines |
US5332736A (en) * | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
KR20010031470A (ko) | 1997-10-28 | 2001-04-16 | 둘락 노먼 씨. | 포유동물의 갈망을 감소시키는 방법 |
AU759756B2 (en) | 1998-10-20 | 2003-05-01 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse |
PT1158973E (pt) | 1999-02-24 | 2005-07-29 | Univ Cincinnati | Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos |
EP1175211A2 (en) | 1999-04-30 | 2002-01-30 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
-
1998
- 1998-12-11 US US09/209,952 patent/US6541520B1/en not_active Expired - Fee Related
-
1999
- 1999-07-28 US US09/362,592 patent/US6593367B1/en not_active Expired - Fee Related
- 1999-08-05 PT PT99941982T patent/PT1102583E/pt unknown
- 1999-08-05 WO PCT/US1999/017220 patent/WO2000007583A2/en not_active Application Discontinuation
- 1999-08-05 AU AU55452/99A patent/AU772715B2/en not_active Ceased
- 1999-08-05 HU HU0103377A patent/HUP0103377A3/hu unknown
- 1999-08-05 CA CA002339192A patent/CA2339192C/en not_active Expired - Fee Related
- 1999-08-05 BR BR9912760-1A patent/BR9912760A/pt not_active Application Discontinuation
- 1999-08-05 PL PL347912A patent/PL198789B1/pl not_active IP Right Cessation
- 1999-08-05 ID IDW20010504A patent/ID28916A/id unknown
- 1999-08-05 MX MXPA01001268A patent/MXPA01001268A/es not_active IP Right Cessation
- 1999-08-05 CZ CZ2001394A patent/CZ2001394A3/cs unknown
- 1999-08-05 CN CNB998117625A patent/CN1172663C/zh not_active Expired - Fee Related
- 1999-08-05 DE DE69931789T patent/DE69931789T2/de not_active Expired - Lifetime
- 1999-08-05 IL IL14106799A patent/IL141067A0/xx unknown
- 1999-08-05 AT AT99941982T patent/ATE328588T1/de active
- 1999-08-05 EP EP99941982A patent/EP1102583B1/en not_active Expired - Lifetime
- 1999-08-05 NZ NZ509682A patent/NZ509682A/en not_active IP Right Cessation
- 1999-08-05 JP JP2000563268A patent/JP2002522383A/ja active Pending
- 1999-08-05 ES ES99941982T patent/ES2267287T3/es not_active Expired - Lifetime
- 1999-08-05 DK DK99941982T patent/DK1102583T3/da active
- 1999-09-29 TW TW088113319A patent/TWI243674B/zh active
-
2000
- 2000-08-09 US US09/635,578 patent/US6323239B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 NO NO20010539A patent/NO20010539L/no not_active Application Discontinuation
- 2001-02-02 US US09/776,117 patent/US6906099B2/en not_active Expired - Fee Related
- 2001-02-02 HR HR20010085A patent/HRP20010085A2/hr not_active Application Discontinuation
-
2006
- 2006-09-05 CY CY20061101262T patent/CY1105214T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20010539D0 (no) | Behandling av avhengighet og avhengighet-relatert oppförsel | |
AU1718400A (en) | Method for treating pain | |
AU6040001A (en) | Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders | |
DE69939864D1 (de) | Ppar-gamma modulatoren | |
PT1318837E (pt) | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio | |
PT1446387E (pt) | Derivados de aril-1,4-pirazina substituídos | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
NO20033440D0 (no) | Behandling av neurologisk dysfunksjon innbefattende fruktopyranosesulfamater og erytropoietin | |
TNSN00010A1 (fr) | DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE. | |
PT799578E (pt) | Preparacao combinada contendo germes enriquecidos com electrolitos | |
IL162182A (en) | Kits containing oral contraceptives and methods utilizing the same | |
PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
DE60128912D1 (en) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
MY122838A (en) | Treating allergic and inflammatory conditions | |
DE60025639D1 (de) | Substituierte diazepan | |
MY106956A (en) | Certain paf antagonist antihistamine combinations and methods. | |
DK1143917T3 (da) | Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom | |
ATE473001T1 (de) | Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
TR200000461T2 (tr) | Bir transdermal terapötik sistemin suistimalinin önlenmesini sağlayan işlem. | |
EE04494B1 (et) | 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena | |
KR970014708U (ko) | 노내 산소 침투방지 장치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |